Trump announces trade deal with EU following months of negotiations
YORK, U.K. - Abingdon Health plc (AIM:ABDX), a prominent developer and supplier of rapid diagnostic tests, has awarded stock options to certain directors and senior managers as part of its Long Term Incentive Plan (LTIP), aiming to align their interests with those of shareholders.
The LTIP, established in December 2022, has granted options for a total of 4,092,000 ordinary shares at 0.025 pence each to selected members of the company’s leadership. These options, which carry no cost, are set to vest by June 30, 2027, contingent upon the achievement of specific total shareholder return targets.
Among the recipients are Executive Chairman Chris Hand, who received 946,000 new options, bringing his LTIP total to 1,658,057 options. Chief Commercial Officer Chris Yates was also awarded 946,000 new options, now holding a total of 3,082,173 under the plan. Other key figures include Chief Financial Officer Tom Hayes with 660,000 new options, Chief Operating Officer Mark Jones with an additional 500,000, and Chief Technical Officer Nina Garrett with 420,000 new options.
The incentive scheme extends to other senior roles, with Candice Vendettuoli, Head of QARA, and Natalie Thrush, Head of HR/Site Lead, receiving 320,000 and 300,000 new options, respectively.
This strategic move by Abingdon Health is part of a broader effort to retain key staff and drive performance by tying their rewards directly to the company’s success as measured by shareholder returns.
The information in this article is based on a press release statement from Abingdon Health plc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.